Identification of biomarkers which reflects the treatments effects of Nivolmab through comprehensive analyses of serum exosmal mRNA derived from the HNSCC patients.

Not Applicable

• Conditions: head and neck squamous cell cancer

• Registration Number: JPRN-UMIN000037029
• Lead Sponsor: Clinical Research Support Center Kyushu

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-06-17
• Study Completion: 2021-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 111

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients who have been given immune checkpoint inhibitors in the past. 2.Patients with ECOG Performance Status 3 or 4 3.Patients under tumor immunotherapy or with plan to be co-administered with other antineoplastic agents. 4.Patients with active double cancer excluding CIS and endoscopically treatable early esophagus cancer. 5.patients judged inappropriate by investigators.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response rate

Secondary Outcome Measures

Name	Time	Method
1-year survival rate